Enhanced Personalized Prescriptions with the Addition of CD Indication

Celltrion has launched the intravenous (IV) formulation of ‘Stekyma’ (active ingredient: ustekinumab), a treatment for autoimmune diseases, in Japan.


On August 21, Celltrion announced that it completed the local launch of the Stekyma IV formulation in Japan approximately four months after obtaining product approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) in April. In addition to the existing indications for psoriasis (PsO) and psoriatic arthritis (PsA), the company has now also secured approval for Crohn’s disease (CD), thereby expanding the range of treatment applications.

Celltrion Stekima (active ingredient Ustekinumab). Celltrion

Celltrion Stekima (active ingredient Ustekinumab). Celltrion

View original image

The Japanese subsidiary of Celltrion aims to drive early market penetration of Stekyma by leveraging its sales expertise built through the promotion of its existing autoimmune disease products such as Remsima (active ingredient: infliximab) and Yuflyma (active ingredient: adalimumab). As of May, Remsima and Yuflyma continued to rank first for biosimilar product prescriptions in Japan, with market shares of 46.9% and 19.5%, respectively.


Patients prescribed Stekyma are able to receive induction therapy at the early stage of the disease through the IV formulation, and subsequently manage their condition over the long term with maintenance therapy using the subcutaneous (SC) formulation. By selecting either the IV or SC formulation of Stekyma depending on disease phase and patient condition, stable therapeutic efficacy can be achieved. Stekyma is currently the only ustekinumab biosimilar launched in Japan that is available in both IV and SC formulations.


The Japanese subsidiary of Celltrion plans to actively promote Stekyma’s product competitiveness at major Japanese conferences for healthcare professionals, including the Digestive Disease Week Japan (JDDW) and Japanese Society for Inflammatory Bowel Diseases (JSIBD), both scheduled to be held in the second half of the year. The company will further strengthen networks with key healthcare providers and pharmacists attending these major conferences and utilize this network as a foundation for the planned launch of ‘Remsima SC’ next year.



A Celltrion official stated, “With the launch of Stekyma’s IV formulation, we now possess both formulations, and this differentiated advantage is expected to increase preference among Japanese healthcare professionals and patients compared to competitors. We plan to leverage our professional networks to lead Stekyma’s early market establishment and further strengthen Celltrion’s influence in the Japanese autoimmune disease market.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing